SOUTH SAN FRANCISCO, Calif., May 05, 2011 (BUSINESS WIRE) -- Exelixis, Inc. (NASDAQ:EXEL) announced today that Michael Morrissey, Ph.D., the company's president and chief executive officer, will present at the upcoming Bank of America Merrill Lynch Health Care Conference at 11:40 a.m. EDT / 8:40 a.m. PDT on Tuesday, May 10, 2011 in Las Vegas. During the presentation, Dr. Morrissey will review the most recent publicly available data for cabozantinib in castration-resistant prostate cancer (CRPC) and discuss the pivotal trial plans and regulatory strategy for the compound in CRPC. He will also discuss the company's 2011 financial outlook and provide a general business update.

The presentation will be webcast and may be accessed in the Event Calendar page under Investors and Media at www.exelixis.com.

About Exelixis

Exelixis, Inc. is a biotechnology company committed to developing small molecule therapeutics for the treatment of cancer. Exelixis is focusing its resources and development efforts exclusively on cabozantinib, its most advanced solely-owned product candidate, in order to maximize the therapeutic and commercial potential of this compound. Exelixis believes cabozantinib has the potential to be a high-quality, differentiated pharmaceutical product that can make a meaningful difference in the lives of patients. Exelixis has also established a portfolio of other novel compounds that it believes have the potential to address serious unmet medical needs. For more information, please visit the company's web site at www.exelixis.com.

SOURCE: Exelixis, Inc.

Exelixis, Inc.
Charles Butler, 650-837-7277
Vice President, Investor Relations and Corporate Communications
cbutler@exelixis.com